As of June 30, 2026, PanGenomic Health, Inc. Class A carries a market capitalization of 5.83M, placing it among publicly traded companies globally. Its enterprise value stands at 6.27M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.83M |
| Enterprise Value | 6.27M |
As of June 30, 2026, PanGenomic Health, Inc. Class A has 25.70M shares outstanding.
| Shares Outstanding | 25.70M |
These figures are as of June 30, 2026.
| PB Ratio | -3.43 |
| P/TBV Ratio | -3.43 |
| P/FCF Ratio | -3.85 |
| P/OCF Ratio | -3.85 |
As of June 30, 2026, PanGenomic Health, Inc. Class A maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -25.97, indicating conservative leverage, while an interest coverage ratio of -196.07 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.05 |
| Quick Ratio | 0.01 |
| Debt / Equity | -25.97 |
| Debt / EBITDA | -0.17 |
| Interest Coverage | -196.07 |
These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -4,309.33, reflecting losses generated across the asset base.
| Return on Assets (ROA) | -4,309.33 |
As of the close on October 22, 2026, PanGenomic Health, Inc. Class A's stock has declined approximately 84.44% over the past 52 weeks. The 50-day moving average sits at 0.17, while the 200-day moving average is 0.23.
| 52-Week Price Change | -84.44% |
| 50-Day Moving Average | 0.17 |
| 200-Day Moving Average | 0.23 |
Over the twelve months ended June 30, 2026, PanGenomic Health, Inc. Class A generated - - in revenue and converted that into -2.62M in net income, yielding earnings per share of -0.11. EBITDA reached -2.59M, while operating income came in at -2.49M.
| Operating Income | -2.49M |
| Pretax Income | -2.62M |
| Net Income | -2.62M |
| EBITDA | -2.59M |
| EBIT | -2.59M |
| Earnings Per Share (EPS) | -0.11 |
As of June 30, 2026, PanGenomic Health, Inc. Class A holds 4,759.47 in cash and equivalents against 441,183.99 in total debt, resulting in a net debt position of 436,424.51. Total book value stands at -1.70M, with working capital of -1.70M providing operational flexibility.
| Cash & Cash Equivalents | 4,759.47 |
| Total Debt | 441,183.99 |
| Net Debt | 436,424.51 |
| Equity (Book Value) | -1.70M |
| Book Value Per Share | -0.07 |
| Working Capital | -1.70M |
PanGenomic Health, Inc. Class A produced -1.36M in operating cash flow over the twelve months ended June 30, 2026.
| Operating Cash Flow | -1.36M |
| Free Cash Flow | -1.36M |
| FCF Per Share | -0.06 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -26.00: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -23.40, meaning PanGenomic Health, Inc. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -23.40 |
| FCF Yield | -26.00 |
PanGenomic Health, Inc. Class A's most recent stock split took place on November 14, 2024 with a 5:1 split ratio.
| Last Split Date | 11/14/2024 |
| Split Ratio | 5:1 |
As of June 30, 2026, PanGenomic Health, Inc. Class A has an Altman Z-Score of -341.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -341.37 |
Already premium?